Hata R, Maeda K, Hermann D, et al. Evolution of brain in-farction after transient focal cerebral ischemia in mice. J Cereb
Blood Flow Metab 2000;20:937–946.
Hermann DM, Kilic E, Hata R, et al. Relationship between
metabolic changes, gene responses and delayed ischemic injury
after mild focal cerebral ischemia in mice. Neuroscience 2001;
104:947–955.
Frankel AD, Pabo CO. Cellular uptake of the Tat protein from
human immunodeficiency virus. Cell 1988;55:1189 –1193.
Green M, Loewenstein PM. Autonomous functional domains
of chemically synthesized human immunodeficiency virus Tat
trans-activator protein. Cell 1988;55:1179 –1188.
Schwarze SR, Ho A, Vocero-Akbani BA, Dowdy SF. In vivo
protein transduction: delivery of a biologically active protein
into the mouse. Science 1999;285:1569 –1572.
Parsadanian A, Cheng Y, Keller-Peck C, et al. Bcl-X is an an- L

tiapoptotic regulator for postnatal CNS neurons. J Neurosci
1998;18:1009 –1019.
Minn AJ, Velez P, Schendel SL, et al. Bcl-x(L) forms an ion
channel in synthetic lipid membranes. Nature 1997;385:353–
357.
Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell
survival. Science 1998;281:1322–1326.
Schulz JB, Weller M, Moskowitz MA. Caspases as treatment
targets in stroke and neurodegenerative disease. Ann Neurol
1999;45:421– 429.
Reed JC. Double identity for proteins of the Bcl-2 family. Na-ture 1997;387:773–776.
Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells:
TAT-p27Kip1 induces cell migration. Nat Med 1998;4:
1449 –1452.
Kilic E, Hermann DM, Hossmann KA. Recombinant tissue
plasminogen activator reduces infarct size after reversible thread
occlusion of middle cerebral artery in mice. NeuroReport 1999;
10:107–111.
Scheld WM. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the
central nervous system. Rev Infect Dis 1989;11:S1669 –S1690.
Egleton RD, Davis TP. Bioavailability and transport of peptides
and peptide drugs into the brain. Peptides 1997;18:1431–1439.
Van de Waterbeemd H, Camenisch G, Folkers G, et al. Estimation of blood-brain barrier crossing of drugs using molecular
size and shape, and H-bonding descriptors. J Drug Target
1998;6:151–165.
Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91:
664 – 668.
Wiessner C, Allegrini PR, Rupalla K, et al. Neuron-specific
transgene expression of Bcl-X but not Bcl-2 genes reduces le- L

sion size after permanent middle cerebral artery occlusion in
mice. Neurosci Lett 1999;268:119 –122.
Schendel SL, Xie Z, Montal MO, et al. Channel formation by
antiapoptotic protein Bcl-2 . Proc Natl Acad Sci USA 1997;94:
5113–5118.
Shimizu S, Eguchi Y, Kamiike W, et al. Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc
Natl Acad Sci USA 1998;95:1455–1459.
Xu L, Koumenis IL, Tilly JL, Giffard RG. Overexpression of
Bcl-X protects astrocytes from glucose deprivation and is asso- L

ciated with higher glutathione, ferritin, and iron levels. Anesthesiology 1999;91:1036 –1046.
Hossmann KA. Glutamate-mediated injury in focal cerebral
ischemia: the exitotoxin hypothesis revised. Brain Pathol 1995;
4:23–36.
